Drug Profile


Alternative Names: EGEN-001; GEN-1 IL-12 DNA-based immunotherapy - Celsion; IL-12 gene therapy - Celsion Corporation; IL-12 gene therapy - EGEN; IL-12 gene therapy - Expression Genetics; Interleukin-12 gene therapy - Celsion Corporation; Interleukin-12 gene therapy - EGEN; Interleukin-12 gene therapy - Expression Genetics; phIL-12-005/PPC

Latest Information Update: 15 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Expression Genetics
  • Developer Celsion Corporation; Gynecologic Oncology Group
  • Class Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Glioblastoma
  • No development reported Colorectal cancer

Most Recent Events

  • 05 Jul 2017 Celsion completes enrolment in the phase I OVATION trial for Ovarian cancer, Fallopian-tube-cancer and Peritoneal-cancer (First-line therapy, neoadjuvant therapy)
  • 05 Jun 2017 Efficacy and pharmacodynamics data from the phase Ib OVATION trial in Ovarian cancer released by Celsion
  • 03 Jun 2017 Interim adverse events data from a phase Ib OVATION trial in Ovarian cancer, fallopian tube cancer and peritoneal cancer were presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top